Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 20

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 20
---
</div>

| ● | Our Alpha DaRT technology and operations are subject to extensive government regulation and oversight both in the United States and 
 abroad, and our failure to comply with applicable requirements could harm our business;                                             |

| ● | We may not receive, or may be delayed in receiving, the necessary marketing authorizations or certifications for its Alpha DaRT technology 
 or any future products or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for our    
 product candidates would have a material adverse effect on our business;                                                                   |

| ● | If we do not obtain and maintain international regulatory registrations, marketing authorizations or certifications for any product 
 candidates we develop, we will be unable to market and sell such product candidates outside of the United States;                   |

| ● | If in the future Alpha DaRT is approved or certified for commercial sale but we are unable to obtain adequate reimbursement or insurance 
 coverage from third-party payors, we may not be able to generate significant revenue;                                                    |

| ● | We may be unable to obtain a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial 
 scale;                                                                                                                                |

| ● | If we are unable to obtain and maintain patent or other intellectual property protection for our Alpha DaRT technology and for any       
 other products or product candidates that we develop, or if the scope of the patent or other intellectual property protection obtained   
 is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our 
 ability to commercialize any product candidates that we may develop, and our technology may be adversely affected;                       |

| ● | We will continue to incur increased costs as a result of operating as a public company, and our management will continue to devote 
 substantial time to new compliance initiatives;                                                                                    |

| ● | Conditions in Israel could materially and adversely affect our business; |

| ● | We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively; and |

| ● | The                                                                                 
 other matters described in the section titled “Risk Factors” beginning on page S-7. |

We caution you against placing undue reliance
on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking
statement is made. Forward-looking statements set forth herein speak only as of the date of this prospectus supplement. We undertake no
obligation to revise forward-looking statements to reflect future events, changes in circumstances, or